Selected article for: "clinical paper and coronavirus disease"
Author: Cortegiani, Andrea; Ingoglia, Giulia; Ippolito, Mariachiara; Giarratano, Antonino; Einav, Sharon
Title: A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
  • Cord-id: h3mdrikn
  • Document date: 2020_3_10
    • ID: h3mdrikn
    Snippet: PURPOSE: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. METHODS: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19
    Document: PURPOSE: COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. METHODS: PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. RESULTS: We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroquine seems to be effective in limiting the replication of SARS-CoV-2 (virus causing COVID-19) in vitro. CONCLUSIONS: There is rationale, pre-clinical evidence of effectiveness and evidence of safety from long-time clinical use for other indications to justify clinical research on chloroquine in patients with COVID-19. However, clinical use should either adhere to the Monitored Emergency Use of Unregistered Interventions (MEURI) framework or be ethically approved as a trial as stated by the World Health Organization. Safety data and data from high-quality clinical trials are urgently needed.

    Search related documents:
    Co phrase search for related documents
    • abstract title and additional information: 1, 2
    • abstract title and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • abstract title and low income middle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • abstract title screening and additional information: 1
    • abstract title screening and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • abstract title screening and low income middle: 1, 2, 3, 4, 5, 6, 7, 8
    • acceptable safety and acute respiratory infection: 1
    • acceptable safety and low income: 1
    • acceptable safety and low income middle: 1
    • acute respiratory infection and additional information: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory infection and low expenditure: 1
    • acute respiratory infection and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory infection and low income middle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory infection and lung include: 1, 2, 3, 4, 5
    • additional information and low income: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • additional information and low income middle: 1, 2, 3, 4, 5, 6, 7, 8, 9